Table 1 Clinical characteristics of adult AML patients
From: Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
Patient identifier | Diagnosis | Sample number | Sample type | Age | Disease status | Time from dignosis (months) | Cytogenetics | Previous therapies for AML |
|---|---|---|---|---|---|---|---|---|
1145 | Therapy-related AML | 1145_2 | Bone marrow | 41 | Diagnosis | 0 | Hyperdipo 43, t(5; 6), t(7; 9), −19, −20, −Y | – |
1145_3 | Bone marrow | 43 | Relapse | 15 | Cytarabine, azacitidine, allogenic HSCT | |||
1064 | Therapy-related AML | 1064_1 | Bone marrow | 37 | Diagnosis | 0 | abn(3) | – |
1064_3 | Bone marrow | 40 | First relapse | 30 | abn(3) | Cytarabine-antracycline, HSCT (MUD) | ||
3443 | AML without maturation | 3443_3 | Bone marrow | 21 | Resistant disease | 1 | del 17p, −2 (both), −17 (both), −5, −6, −7, −11, −12, −18, −22, +13,+21, 6–8 marker chromosomes | Cytarabine-antracycline |
3443_6 | Bone marrow | 22 | Resistant disease | 4 | As above, 8–12 marker chromosomes | Cytarabine-antracycline, ruxolitinib-everolimus, clofarabine-cytarabine |
